Preterm rupture of the membranes: combination therapy.
Preterm rupture of the membranes poses perhaps the greatest threat to perinatal survival. Unfortunately, the literature leaves us in a quandry as to the management of the problem. At the Medical University of South Carolina for the past 3 years, aspects of both active and passive management have been used. Vaginal pool phospholipid analysis, the use of corticosteroids whenever appropriate, and tocolysis (in an attempt to gain 48 hours) were used in 96 consecutive patients with premature rupture of the membranes between 26 and 36 weeks' gestation. Decisions about delivery were dictated by spontaneous onset of labor and/or evidence of chorioamnionitis. This regimen prolonged gestation an average of 4.6 days. Maternal and neonatal infectious morbidity was uncommon. Clinical chorioamnionitis was diagnosed in 5.2% of mothers, and only 8.5% of all neonates had evidence of serious infection. Respiratory distress syndrome was seen in 12.8% of neonates. There were only three perinatal deaths, and most babies (92.5%) were discharged without residual problems (average hospital stay, 18.1 days). A detailed analysis of the group by gestational age categories will be presented.
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001034:Apgar Score; D001623:Betamethasone / Q000627:therapeutic use; D001724:Birth Weight; D001826:Body Fluids / Q000032:analysis; D002821:Chorioamnionitis / Q000188:drug therapy; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000378:metabolism / Q000517:prevention & control / Q000628:therapy*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D007751:Labor, Induced; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D010743:Phospholipids / Q000032:analysis; D011247:Pregnancy; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology; D012312:Ritodrine / Q000008:administration & dosage / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D010743:Phospholipids; D001623:Betamethasone; D012312:Ritodrine